Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DYN
stocks logo

DYN

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-0.933
+33.34%
--
--
-0.953
-0.77%
--
--
-0.949
+7.84%
Estimates Revision
Stock Price
Go Down
down Image
-3.32%
In Past 3 Month
15 Analyst Rating
up Image0
Wall Street analysts forecast DYN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DYN is 38.97 USD with a low forecast of 10.00 USD and a high forecast of 66.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
2 Hold
0 Sell
Strong Buy
up Image0
Current: 9.020
sliders
Low
10.00
Averages
38.97
High
66.00
up Image0
Current: 9.020
sliders
Low
10.00
Averages
38.97
High
66.00
Evercore ISI
Gavin Clark-Gartner
Outperform
downgrade
$46 -> $41
2025-07-11
Reason
Evercore ISI
Gavin Clark-Gartner
Price Target
$46 -> $41
2025-07-11
downgrade
Outperform
Reason
Evercore ISI analyst Gavin Clark-Gartner lowered the firm's price target on Dyne Therapeutics to $41 from $46 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a "notable lengthening" of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note.
JonesResearch
NULL -> Buy
initiated
$30
2025-06-25
Reason
JonesResearch
Price Target
$30
2025-06-25
initiated
NULL -> Buy
Reason
Bernstein
Bernstein
Market Perform
initiated
$13
2025-06-24
Reason
Bernstein
Bernstein
Price Target
$13
2025-06-24
initiated
Market Perform
Reason
Baird
Outperform -> NULL
downgrade
$46 -> $32
2025-06-19
Reason
Baird
Price Target
$46 -> $32
2025-06-19
downgrade
Outperform -> NULL
Reason
Baird lowered the firm's price target on Dyne Therapeutics to $32 from $46 and keeps an Outperform rating on the shares. The firm updated its model following the swapping of the DYNE-101 endpoint from splicing to vHOT.
Raymond James
Martin Auster
Outperform
initiated
$37
2025-06-10
Reason
Raymond James
Martin Auster
Price Target
$37
2025-06-10
initiated
Outperform
Reason
Raymond James analyst Martin Auster assumed coverage of Dyne Therapeutics with an Outperform rating and $37 price target as part of a broader research note on selection Biotech names. Risk/reward skews favorably across the sector, though while companies with high PoS - probability of success - lead assets allow for higher conviction, highly attractive skews on less de-risked assets may deliver the most outsized returns, the analyst tells investors in a research note. For the stock, the firm notes that while it is trading at an enterprise value below $1B, Dyne's increasingly clinically-validated FORCE platform offers a compelling long-term risk-reward with proof of concept established on two assets in valuable, high unmet need markets, Raymond James added.
Oppenheimer
Andreas Argyrides
Outperform
downgrade
$60 -> $34
2025-06-02
Reason
Oppenheimer
Andreas Argyrides
Price Target
$60 -> $34
2025-06-02
downgrade
Outperform
Reason
Oppenheimer analyst Andreas Argyrides assumed coverage of Dyne Therapeutics with an Outperform rating with a price target of $34, down from $60, after the company reported its Q1 and highlighted progress across its DM1 and Duchenne muscular dystrophy programs. In the Phase 1/2 ACHIEVE trial of DYNE-101 in DM1, following the recent compelling data, the firm is encouraged to see the registrational expansion cohort staying on track for readout in the first half of 2026. Management highlighted its recent participation in a CDER Type C held in May 2025 for DYNE-101 in DM1, and plans to provide a regulatory update following receipt of meeting minutes. In the Phase 1/2 DELIVER trial of DYNE-251 in DMD, the registrational expansion cohort readout remains expected in late 2025.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Dyne Therapeutics Inc (DYN.O) is -2.49, compared to its 5-year average forward P/E of -5.70. For a more detailed relative valuation and DCF analysis to assess Dyne Therapeutics Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.70
Current PE
-2.49
Overvalued PE
-2.32
Undervalued PE
-9.07

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.94
Current EV/EBITDA
-1.47
Overvalued EV/EBITDA
-0.71
Undervalued EV/EBITDA
-7.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 701.06% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

DYN News & Events

Events Timeline

(ET)
2025-07-01
06:05:05
Dyne Therapeutics 24.2M share Spot Secondary priced at $8.25
select
2025-06-30 (ET)
2025-06-30
16:07:08
Dyne Therapeutics files $200M common stock offering
select
2025-06-17 (ET)
2025-06-17
10:38:28
Dyne having vHOT as primary endpoint 'encouraging,' says H.C. Wainwright
select
Sign Up For More Events
Sign Up For More Events

News

Preview
7.0
07-18Globenewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

  • Investigation into Dyne Therapeutics: Pomerantz LLP is investigating potential securities fraud by Dyne Therapeutics and its executives following a delay in FDA approval for their experimental therapy DYNE-101, which caused a significant drop in the company's stock price.

  • Revised Timeline for Clinical Trials: Dyne Therapeutics has revised its timeline for completing enrollment in its Phase 1/2 trial for DYNE-101, now aiming for late 2025 instead of mid-2025, with data readout expected in mid-2026 and potential regulatory submission in late 2026.

Preview
5.0
07-16NASDAQ.COM
Wednesday 7/16 Insider Buying Report: DYN, HELE

  • Dyne Therapeutics Insider Purchase: CEO John Cox purchased 100,000 shares of DYN for $911,000 at $9.11 each, while the stock is currently trading lower at $8.77, despite a 7.7% increase on Wednesday.

  • Helen of Troy Insider Purchase: CEO Brian Grass bought 10,000 shares of Helen of Troy for $214,700 at $21.47 each, with the stock experiencing an 11.8% rise on the same day.

Preview
5.0
07-16SeekingAlpha
Dyne shares up after CEO buys stock

  • CEO Stock Purchase: Dyne Therapeutics' CEO, John Cox, purchased 100,000 shares of the company, contributing to a 6% rise in stock price.

  • Investment Details: The shares were bought at prices ranging from $9.02 to $9.15 each, totaling approximately $911,000.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Dyne Therapeutics Inc (DYN) stock price today?

The current price of DYN is 9.02 USD — it has decreased -4.04 % in the last trading day.

arrow icon

What is Dyne Therapeutics Inc (DYN)'s business?

Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.

arrow icon

What is the price predicton of DYN Stock?

Wall Street analysts forecast DYN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DYN is 38.97 USD with a low forecast of 10.00 USD and a high forecast of 66.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Dyne Therapeutics Inc (DYN)'s revenue for the last quarter?

Dyne Therapeutics Inc revenue for the last quarter amounts to -122.37M USD, increased 76.95 % YoY.

arrow icon

What is Dyne Therapeutics Inc (DYN)'s earnings per share (EPS) for the last quarter?

Dyne Therapeutics Inc. EPS for the last quarter amounts to -106874000.00 USD, increased 35.75 % YoY.

arrow icon

What changes have occurred in the market's expectations for Dyne Therapeutics Inc (DYN)'s fundamentals?

The market is revising No Change the revenue expectations for DYN for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -3.32%.
arrow icon

How many employees does Dyne Therapeutics Inc (DYN). have?

Dyne Therapeutics Inc (DYN) has 191 emplpoyees as of July 19 2025.

arrow icon

What is Dyne Therapeutics Inc (DYN) market cap?

Today DYN has the market capitalization of 1.24B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free